Haitao Cui Sells 3,291 Shares of Foxx Development (NASDAQ:FOXX) Stock

Foxx Development Holdings Inc. (NASDAQ:FOXX) EVP Haitao Cui sold 3,291 shares of Foxx Development stock in a transaction that occurred on Friday, March 20th. The stock was sold at an average price of $4.54, for a total value of $14,941.14. Following the completion of the transaction, the executive vice president owned 133,307 shares of the company’s stock, valued at approximately $605,213.78. The trade was a 2.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Haitao Cui also recently made the following trade(s):

• On Wednesday, March 18th, Haitao Cui sold 156 shares of Foxx Development stock. The shares were sold at an average price of $4.50, for a total value of $702.00.
• On Thursday, March 19th, Haitao Cui sold 603 shares of Foxx Development stock. The stock was sold at an average price of $4.56, for a total value of $2,749.68.

Foxx Development Price Performance

Foxx Development stock opened at $4.20 on Friday. The company has a market cap of $29.42 million, a PE ratio of -1.86 and a beta of -0.28. The company has a fifty day moving average price of $4.54 and a two-hundred day moving average price of $4.40. Foxx Development Holdings Inc. has a 12 month low of $1.71 and a 12 month high of $8.88.

Foxx Development (NASDAQ:FOXX) last issued its earnings results on Friday, February 13th. The company reported ($0.62) earnings per share for the quarter. The business had revenue of $16.72 million for the quarter.

Institutional Investors Weigh In On Foxx Development

An institutional investor recently bought a new position in Foxx Development stock. Citadel Advisors LLC bought a new stake in Foxx Development Holdings Inc. (NASDAQ:FOXX) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 12,025 shares of the company’s stock, valued at approximately $57,000. Citadel Advisors LLC owned about 0.18% of Foxx Development as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 60.44% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Foxx Development in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell”.

Foxx Development Company Profile

Foxx Development, Inc (NASDAQ: FOXX) operates as a contract manufacturer specializing in the design, assembly and distribution of medical devices and components. The company’s core business centers on phlebotomy and blood collection products, serving clinical laboratories, hospitals and diagnostic testing facilities. Its product portfolio includes evacuated blood collection tubes, safety-engineered winged blood collection sets, syringes and ancillary devices used in specimen collection and handling.

Founded in North Carolina, Foxx Development maintains a manufacturing and distribution campus in Apex, where it integrates engineering, quality control and regulatory compliance under one roof.